2015年8月
Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
DIABETES & METABOLISM JOURNAL
- 巻
- 39
- 号
- 4
- 開始ページ
- 342
- 終了ページ
- 347
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.4093/dmj.2015.39.4.342
- 出版者・発行元
- KOREAN DIABETES ASSOC
Background: Predictive factors for the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors for lowering glycosylated hemoglobin (HbA1c) remain unclear in patients with type 2 diabetes mellitus. The aim of this study is therefore to clarify predictive factors of the efficacy of DPP-4 inhibitors for lowering HbA1c after 12 months of treatment.
Methods: A total of 191 consecutive type 2 diabetic patients (male sex 55%, mean age, 68.3 +/- 35.8 years), who had been treated with DPP-4 inhibitors for 12 months, were enrolled in this study and evaluated retrospectively.
Results: After 12 months of DPP-4 inhibitor treatment, random blood glucose level, and HbA1c level, decreased from 167 +/- 63 to 151 +/- 49 mg/dL (P < 0.01), and from 7.5% +/- 1.3% to 6.9% +/- 0.9% (P < 0.01) respectively, without severe side effects. Multiple regression analysis showed that predictors of DPP-4 inhibitor treatment efficacy in lowering HbA1c level after 12 months were a decrease in HbA1c level after 3 months of treatment, a high baseline HbA1c level, a low baseline body mass index, and the absence of coronary artery disease.
Conclusion: Most suitable candidates for treatment with DPP-4 inhibitors are diabetics who are not obese and do not have coronary artery disease. In addition, long-term efficacy of DPP-4 inhibitors can be predicted by decrement of HbA1c after 3 months of treatment.
Methods: A total of 191 consecutive type 2 diabetic patients (male sex 55%, mean age, 68.3 +/- 35.8 years), who had been treated with DPP-4 inhibitors for 12 months, were enrolled in this study and evaluated retrospectively.
Results: After 12 months of DPP-4 inhibitor treatment, random blood glucose level, and HbA1c level, decreased from 167 +/- 63 to 151 +/- 49 mg/dL (P < 0.01), and from 7.5% +/- 1.3% to 6.9% +/- 0.9% (P < 0.01) respectively, without severe side effects. Multiple regression analysis showed that predictors of DPP-4 inhibitor treatment efficacy in lowering HbA1c level after 12 months were a decrease in HbA1c level after 3 months of treatment, a high baseline HbA1c level, a low baseline body mass index, and the absence of coronary artery disease.
Conclusion: Most suitable candidates for treatment with DPP-4 inhibitors are diabetics who are not obese and do not have coronary artery disease. In addition, long-term efficacy of DPP-4 inhibitors can be predicted by decrement of HbA1c after 3 months of treatment.
- リンク情報
- ID情報
-
- DOI : 10.4093/dmj.2015.39.4.342
- ISSN : 2233-6079
- eISSN : 2233-6087
- PubMed ID : 26301197
- Web of Science ID : WOS:000368002900010